...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>International journal of clinical pharmacology and therapeutics >Dose linearity and steady state pharmacokinetics of the new antiparkinson agent budipine after oral administration.
【24h】

Dose linearity and steady state pharmacokinetics of the new antiparkinson agent budipine after oral administration.

机译：新型抗帕金森药物布地平口服后的剂量线性和稳态药代动力学。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The dose-dependency of budipine pharmacokinetic characteristics was studied. Eighteen healthy male subjects were given 10, 20 and 30 mg oral single doses according to a randomized, open, 3-period crossover design. Additionally, the steady state conditions were investigated after repeated intake of 10 mg t.i.d for 10 days and compared to the 10 mg single dose. The area under the concentration vs time curve (AUC) and the maximum serum concentration (Cmax) showed a linear increase in line with ascending doses of orally given budipine. Time to maximum serum concentration (tmax) and terminal half-life (t1/2) were independent of the administered dose. As compared to the 10 mg single dose pharmacokinetics, the repeated oral administration of budipine 10 mg t.i.d. resulted in an increase in AUC of 11% and 93% for budipine and its metabolite p-OH-budipine, respectively. In clinical practice, a predictable response in proportion to the dose is to be expected.
机译：研究了布地平药代动力学特征的剂量依赖性。根据随机，开放，三期交叉设计，对18名健康男性受试者分别给予10、20和30 mg口服单剂。另外，在重复摄入10mg t.i.d 10天后研究稳态条件，并与10mg单剂量比较。浓度与时间的曲线下面积（AUC）和最大血清浓度（Cmax）随口服布地平的剂量增加呈线性增加。达到最大血清浓度的时间（tmax）和终末半衰期（t1 / 2）与给药剂量无关。与10 mg单剂量药代动力学相比，布地平10 mg t.i.d的重复口服给药。导致布地平及其代谢物p-OH-budipine的AUC分别增加11％和93％。在临床实践中，预期与剂量成比例的可预期的反应。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号